What are the characteristics of ONWARD MEDICAL stock?

ONWARD MEDICAL is a company operating in the Dispositifs médicaux sector. The stock is listed on Euronext Brussels under ISIN NL0015000HT4.

What is the recent price evolution of ONWARD MEDICAL stock?

Since last close: -1.28 %. Over one week: 7.8 %. Over one year: -47.47 %.

ONWARD Medical: Coverage Initiated by Portzamparc with a Buy Recommendation

Portzamparc – BNP Paribas Group has initiated coverage of ONWARD Medical with a buy recommendation and a target price of EUR 10.20.

Published on Oct 15, 2025 at

ONWARD MEDICAL

2.70 € -1.28 %

Add us as a preferred source on Google

Coverage Initiation

ONWARD Medical N.V., specializing in neurotechnologies, announces that Portzamparc – BNP Paribas Group has started covering its stock. This coverage comes with a buy recommendation and a target price set at EUR 10.20 per share. This decision follows the market approvals of the ARC-EX® system in the United States and Europe, marking a significant milestone for ONWARD in its commercial development.

Strategic Developments

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

According to Dave Marver, CEO of ONWARD Medical, the year 2025 is pivotal for the company, with not only the commercial authorization of the ARC-EX® system but also the planned launch of the first pivotal study for the implantable ARC-IM® platform. The company continues to strengthen its position in the field of brain-computer interface (BCI) assisted mobility, which could enhance its leadership in this emerging sector.

Analyst Confidence

The initiation note from Portzamparc, published on October 7, 2025, brings the number of banking institutions covering ONWARD Medical's stock to five. All these institutions maintain a buy recommendation, demonstrating a certain confidence among analysts in the company's growth prospects. This increase in recommendations could positively influence investor interest in the stock.

🏢 Other stocks — Santé

🗞️ Sanofi shares lose ground and fall back to their lowest level in a year 🗞️ Abivax stock declines but retains nearly 38% gain over one year 🗞️ Medincell stock plunges 22% in three months and breaks through its support levels 🗞️ MaaT Pharma: Negative CHMP Voting Trend on MaaT013 (Xervyteg)

Context

Period

Period: S1 2026

Key reported figures

Revenue: 3,4 millions d'euros
Quarterly revenue: 3,4 millions d'euros
Net income: -24,7 millions d'euros
-81,5 millions d'euros

Risks mentioned

Regulatory approvals delays could impact commercial expansion timelines
Competition and technology changes could affect market positioning
Continued significant operating losses require sustained funding

Opportunities identified

ARC-EX home-use expansion in US Veterans Affairs and additional countries planned for H2 2026
Empower BP global pivotal study advancement with 22 enrolled participants and 14 active clinical sites
Pipeline expansion with planned first clinical feasibility study for bladder function restoration and additional indications exploration

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Coverage Initiation

Strategic Developments

Analyst Confidence

Context

Also read